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Abstract
Non-amyloidogenic K-secretase processing of amyloid precursor protein (APP) is stimulated by protein kinase C (PKC).
Levels and activity of PKC are decreased in sporadic Alzheimer’s disease skin fibroblasts. We investigated whether
alterations in PKC and PKC-mediated APP processing occur also in fibroblasts established from individuals with familial
Alzheimer’s disease APP KM670/671NL, PS1 M146V and H163Y mutations. These pathogenic mutations are known to
alter APP metabolism to increase AL. PKC activities, but not levels, were decreased by 50% in soluble fractions from
sporadic Alzheimer’s disease cases. In contrast, familial Alzheimer’s disease fibroblasts showed no significant changes in
PKC enzyme activity. Fibroblasts bearing the APP KM670/671NL mutation showed no significant differences in either PKC
levels or PKC-mediated soluble APP (APPs) secretion, compared to controls. Fibroblasts bearing PS1 M146V and H163Y
mutations showed a 30% increase in soluble PKC levels and a 40% decrease in PKC-mediated APPs secretion. These results
indicate that PKC deficits are unlikely to contribute to increased AL seen with APP and PS1 mutations, and also that PS1
mutations decrease K-secretase derived APPs production independently of altered PKC activity. ß 1999 Elsevier Science
B.V. All rights reserved.
Keywords: Alzheimer’s disease; Protein kinase C; Fibroblast ; Amyloid precursor protein; Presenilin
1. Introduction
Alzheimer’s disease is characterised neuropatho-
logically by the deposition of extracellular amyloid
plaques containing aggregates of the AL peptide [1],
as well as intracellular neuro¢brillary tangles com-
posed primarily of abnormally phosphorylated tau
protein [2]. AL is a 39^43-amino-acid, self-aggregat-
ing peptide that is cleaved from the amyloid precur-
sor protein (APP). APP is a transmembrane glyco-
protein with a long extracellular N-terminus and a
short intracellular C-terminus that is processed by
di¡erent pathways to yield both secreted and cell-
associated derivatives. The K-secretase processing of
APP involves cleavage within the AL region to yield
a large N-terminal ectodomain (APPs) [3^5] and a
10 kDa C-terminal product which can undergo an
additional cleavage. This leads to the formation of
a 3 kDa AL fragment, known as p3 [6] and its com-
plementary product p7. These K-secretase proteolytic
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cleavage products are thought to be non-amyloido-
genic [7]. AL is generated when APP is cleaved by L-
secretase at the N-terminus and by Q-secretase at the
C-terminus of the AL domain. APP can also be de-
graded in an endosomal^lysosomal compartment re-
sulting in multiple fragments some of which contain
the intact AL domain and are therefore potentially
amyloidogenic [5,8]. K-Secretase processing of APP
can be regulated by receptor-coupled protein kinase
C (PKC)-dependent, as well as PKC-independent
mechanisms [9^14]. However, increased production
of APPs does not always result in decreased produc-
tion of AL, suggesting that the regulation of APP
metabolism is cell type-speci¢c [15]. Decreased levels
of AL production following phorbol ester-stimulated
release of APPs has been shown to occur in APP-
transfected COS-, CHO-, and HEK293-cells [16^19]
as well as in ¢broblasts [20]. In contrast, AL and
APPs generation appear to be independent of each
other in human neuroblastoma SH-SY5Y cells [21].
Molecular genetic studies have identi¢ed Alzheim-
er’s disease causing mutations in the APP gene on
chromosome 21 and in the Presenilin 1 (PS1) and
Presenilin 2 genes on chromosome 14 and chromo-
some 1, respectively. APP gene mutations include a
double mutation at codons 670 and 671 which was
found in a large Swedish family with dominantly
inherited, early onset Alzheimer’s disease [22]. Stud-
ies of cultured skin ¢broblasts from members of the
Swedish APP KM670/671NL family have shown that
cellular production of the AL peptide is increased
approximately three fold in mutation carrying cell
lines [20,23]. Mutations in the PS1 gene have been
found in approximately 45 families including one
Swedish family (Swed2) at codon H163Y and one
Swedish/Finnish family at codon M146V [24]. Muta-
tions in the PS1 gene have been reported to cause a
speci¢c increase in the cellular production of more
¢brillogenic forms of the AL peptide ending at amino
acids 42/43 [25^28].
Increased AL peptide production due to APP and
PS1 mutations has also been shown in primary skin
¢broblasts from a¡ected individuals [29,30]. Skin ¢-
broblasts have also been used to look at a range of
other biological changes in Alzheimer’s disease in-
cluding that of an altered PKC level and activity
[31,32]. Decreased cytosolic PKC activity has been
shown in cultured ¢broblasts from both sporadic
and familial Alzheimer’s disease cases [33^35]. After
characterising the di¡erent PKC isoforms in ¢bro-
blasts [36], it was shown that reduced PKC activity
in sporadic Alzheimer’s disease ¢broblasts could be
explained by a speci¢c 30% reduction of the cytosolic
PKCK isoform [37].
Since both the Swedish APP KM670/671NL mu-
tation and the PS1 H163Y and PS1 M146V muta-
tions show an altered APP metabolism, we felt it
important to investigate whether these phenotypes
included PKC de¢cits that would contribute to al-
tered K-secretase APP processing and the reported
increased AL peptide production. In this study we
have looked at PKC levels and activity in soluble
and particulate fractions from mutation-bearing
and control skin ¢broblasts. PKC activities were de-
termined as the phosphorylation of endogenous his-
tone H III-SS substrate. A binding assay with
[3H]phorbol-12,13-dibutyrate (PdBu) was also used
to estimate the amount of total PKC. Basal and
PKC-stimulated APPs release were determined by
immunoblotting of cell culture media with the mono-
clonal antibody 22C11.
2. Materials and methods
2.1. Cell culture
Skin biopsies taken from the upper arm of mem-
bers of the Swedish family with the APP KM670/
671NL mutation, the Swedish family with the PS1
H163Y mutation as well as the Swedish/Finnish fam-
ily with the PS1 M146V mutation were explanted
and grown in minimum essential medium with
Earle’s salts (EMEM), supplemented with 10% foetal
bovine serum (FBS), 2 mM L-Glutamine, 100 units/
ml penicillin, 100 Wg/ml streptomycin, 60 Wg/ml Ty-
locine (Anti-PPLO agent), 20 mM Tricine bu¡er (pH
7.4) and 1% v/v non-essential amino acid solution
(Gibco BRL, Life Technologies, European Division)
at 37‡C in humidi¢ed air with 5% CO2. Cell lines
originated from sporadic Alzheimer’s disease (AD)
cases and age-matched controls were obtained either
from the Cell Repository at the IRCCS ‘Centro S.
Giovanni di Dio-FBF’, Brescia, or from the NIA
Aging Cell Repository, USA, and grown under the
same conditions. Case and cell line details are given
BBADIS 61813 22-3-99
M. Vestling et al. / Biochimica et Biophysica Acta 1453 (1999) 341^350342
in Table 1. Sporadic AD refers to individuals without
a known family history of AD. Familial controls
refers to non-mutation-bearing individuals within a
mutation-bearing family.
2.2. Preparation of soluble and particulate fractions
The cells were treated for 5 min with EDTA-sol-
ution (1 mM EDTA in phosphate-bu¡ered saline
(PBS), pH 7.2) and then harvested with 0.025% tryp-
sin in Ca2 and Mg2 free PBS (Gibco BRL) at
con£uence 5^7 days after previous subculture. Har-
vested cells were washed twice in PBS and thereafter
frozen as pellets and stored at 370‡C. The pellets
were thawed and re-suspended in 20 mM Tris^HCl
(pH 7.4) containing 0.32 M sucrose, 2 mM EDTA,
50 mM L-mercaptoethanol, 50 Wg/ml phenylmethyl-
sulfonyl£uoride, 20 Wg/ml leupeptin and 25 Wg/ml
aprotinin (bu¡er A), and homogenised using a glass
Te£on homogenizer. Cell homogenates were centri-
fuged at 100 000Ug for 30 min. Pellets were re-sus-
pended in the same volume of bu¡er A and centri-
fuged for 30 min at 100 000Ug. The pooled
supernatants constituted the soluble PKC fraction.
The pellets were re-suspended in bu¡er A and div-
ided into two parts, one was used as the membrane
suspension in the binding experiments. The other was
treated with 0.5% Triton X-100 on ice for 45 min and
after sonication centrifuged at 100 000Ug for 30 min.
The supernatant represented the solubilised particu-
late PKC fraction. Protein levels were determined
according to Bradford [38] and homogenates then
aliquoted and frozen at 370‡C.
2.3. Protein kinase C enzyme activities
To determine PKC enzyme activities, 7^10 Wg of
soluble or solubilised particulate cell homogenate
were incubated at 37‡C in 250 Wl bu¡er containing
20 mM Tris^HCl, 5 mM Mg(CH3COO)2 and 1.25 Wg
histone H III-SS. The phosphorylation was started
after 5 min pre-incubation by adding 5 nmol
[Q-33P]ATP ([Q-33P]ATP, Du Pont NEN, 2000 Ci/
mmol; 0.24 pmol [Q-33P]ATP diluted with 5 nmol
cold ATP). Basal activity was measured in the pres-
ence of 2 mM ethylene glycol tetraacetic acid. Stimu-
lated activity was measured in the presence of 2 mM
CaCl2, 10 Wg phosphatidylserine and 1 Wg diolein.
These conditions have been reported to fully stimu-
late PKC [39,40]. Reactions were stopped by 25%
trichloroacetic acid precipitation and ¢ltering onto
Millipore HA 0.45-mm ¢lters. Filter bound radioac-
tivity was determined by scintillation spectroscopy
and enzyme activities were expressed as pmol phos-
phorylated histone/mg protein per minute. Experi-
ments were repeated 2^4 times for each cell line.
2.4. [3H]Phorbol-12,13-dibutyrate binding
PKC levels were determined by performing single
concentration binding assays with [3H]phorbol-
12,13-dibutyrate ([3H]PdBu, Du Pont NEN, 20 Ci/
mmol). Seven to 14 Wg protein of either soluble or
particulate fractions was incubated with 10 nM
[3H]PdBu in a ¢nal volume of 500 Wl reaction mix
containing 20 mM Tris^HCl (pH 7.5), 2 mM CaCl2,
1 mg/ml BSA, 50 mM L-mercaptoethanol, 100 Wg/ml
phosphatidylserine. 100WM PdBu was used to de¢ne
non-speci¢c binding. Soluble fractions were incu-
bated for 15 min at 23‡C after which 400 Wl of
10% DEAE was added, and samples then incubated
for 15 min 0‡C. Particulate fractions were incubated
for 60 min at 23‡C. After incubations the mixtures
were ¢ltered through Whatman GF/C ¢lters that had
been pre-soaked in 0.05% polyethyleneimine. Filter-
bound radioactivity was determined by scintillation
spectroscopy. Each cell line was assayed in triplicate.
2.5. APPs Western blotting
APPs levels were determined by Western-blot anal-
ysis. Con£uent cells in T25 £asks were rinsed twice
with 2 ml of fresh culturing medium and then stimu-
lated with 1 WM PdBu in 1 ml EMEM supplemented
with 10% FBS, 2 mM L-Glutamine, 100 units/ml
penicillin and 100 Wg/ml streptomycin (Gibco BRL)
for 2 h at 37‡C. Media were thereafter transferred to
Eppendorf tubes, snap frozen and stored at 370‡C
until assayed. Protein quanti¢cations were performed
by BCA Protein Assay (Pierce, USA) and the pro-
teins were separated by sodium dodecyl sulfate^
polyacrylamide gel electrophoresis [41] using 10%
acrylamide gels. Proteins were transferred electro-
phoretically onto Protran nitrocellulose membrane
(Schleicher and Schuell, Germany). After blocking
for 1 h using 5% (w/v) dried milk in Tris-bu¡ered
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Table 1
Genotype, clinical status, age of patient when biopsy was taken, family and gender of individuals from whom cell lines were used
Patient/genotype Disease status Age (years) Gender
Sporadic cases (mean age ( þ S.D.) 76 þ 11 years)
ITA 4 AD 82 F
ITA 5 AD 74 F
ITA 8 AD 86 F
AG06265 AD 61 M
Controls (mean age ( þ S.D.) 57 þ 9 years)
ITA 9 Control 45 M
ITA 17 Control 67 M
AG09878 Control 61 F
AG11362 Control 63 F
AG07123 Control 62 M
AG11154 Control 47 M
AG07139 Control 53 F
APP KM670/671NL (mean age ( þ S.D.) : +/3 55 þ 8 years; 3/3 64 þ 15 years)
+/3 AD 66 F
+/3 AD 58 F
+/3 AD 64 M
+/3 Pre-symptomatic 42 F
+/3 Early symptomatic 53 M
+/3* Pre-symptomatic 49 F
+/3 AD 54 M
3/3 Non-mutant 70 M
3/3 Non-mutant 62 M
3/3 Non-mutant 59 M
3/3 Non-mutant 52 F
3/3 Non-mutant 75 F
3/3 Non-mutant 88 F
3/3 Non-mutant 44 F
PS1 H163Y (mean age ( þ S.D.): +/3 46 þ 11 years; 3/3 45 þ 16 years)
+/3 AD 55 F
+/3 AD 59 M
+/3 Pre-symptomatic 31 M
+/3 Pre-symptomatic 44 M
+/3 Pre-symptomatic 42 M
3/3 Non-mutant 64 F
3/3 Non-mutant 35 M
3/3 Non-mutant 37 M
PS1 M146V (mean age ( þ S.D.) : +/3 42 years; 3/355 þ 9 years)
+/3 AD 43 F
+/3 AD 41 F
3/3 Non-mutant 37 F
3/3 Non-mutant 39 M
3/3 Non-mutant 36 F
3/3 Non-mutant 30 F
Mean age ( þ S.D.) PS1 pooled: +/3 45 þ 9 years; 3/3 40 þ 11 years. AD, Alzheimer’s disease.
*See Fig. 2.
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solution containing 0.1% Tween-20 (TBS-t), the
membranes were incubated for 3 h at room temper-
ature (RT) with a 2500-fold dilution of the primary
monoclonal antibody 22C11 (Boehringer Mannheim,
Germany). Nitrocellulose membranes were rinsed in
TBS-t for 15 min and then three times for 5 min,
prior to a 1-h incubation at RT with a 2000-fold
dilution of the secondary antibody (anti-mouse
horseradish peroxidase linked). Thereafter, the mem-
branes were washed overnight and bands detected by
the ECL method (Amersham, UK). The relative den-
sity of immunoreactive bands on Western blots was
calculated from the area multiplied by the optical
density of selected bands, following acquisition of
the blot image through Image Master (Pharmacia
Biotech). The Western blotting for APPs were per-
formed once for the APP mutation-bearing cell lines
and as three separate repeat experiments for the PS1
mutation-bearing cell lines.
3. Results
3.1. PKC activity
PKC activities were signi¢cantly decreased by ca.
50% in soluble fractions from sporadic Alzheimer’s
disease patients, compared to age-matched controls
(Table 2). No signi¢cant di¡erences were seen in
soluble PKC activity between mutation-bearing and
control cell lines established from individuals of the
Swedish APP KM670/671NL double mutation fam-
ily (Table 2). Similarly PKC activities in soluble frac-
tions from cell lines with and without PS1 mutations
were not signi¢cantly di¡erent (Table 2). PKC activ-
ities in the particulate fractions were below the assay
detection limit.
3.2. PKC levels
[3H]Phorbol-12,13-dibutyrate binding studies re-
vealed no signi¢cant di¡erences in PKC levels be-
tween sporadic Alzheimer’s disease cases and con-
trols in either soluble or particulate fractions (Table
3). Similarly, neither soluble or particulate fractions
from APP KM670/671NL mutation-bearing cell lines
showed di¡erences in PKC levels, compared to con-
trols (Table 3). In contrast, levels of PKC in soluble,
but not in particulate, fractions from ¢broblast cell
lines with PS1 mutations were signi¢cantly increased
by ca. 30% when compared with controls (Table 3).
3.3. PKC-stimulated APPs release
Fig. 1 shows a representative immunoblot from an
experiment of basal and PdBu induced APPs secre-
Table 3
PKC levels in soluble and particulate fractions from sporadic,
APP and PS1 mutation-bearing ¢broblasts
Group AD/Mut Controls
Sporadics
Soluble 4.69 þ 2.7 5.18 þ 1.5
Particulate 1.34 þ 0.7 2.76 þ 3.2
APP KM670/671NL
Soluble 7.05 þ 2.4 6.56 þ 1.9
Particulate 2.21 þ 0.7 2.21 þ 0.4
PS1 mutations
Soluble 9.80 þ 1.6* 7.45 þ 1.6
Particulate 2.22 þ 0.7 2.34 þ 0.7
The mean values ( þ S.D.) are shown as pmol/mg protein. Sig-
ni¢cance was determined using Student’s unpaired t-test;
*P6 0.05 compared to non-mutation carriers or controls.
Table 2
PKC activity in soluble fractions from sporadic, APP and PS1
mutation-bearing ¢broblasts
Group AD/Mut Controls
Sporadics 86 þ 55* 174 þ 64
APP KM670/671NL 210 þ 97 206 þ 53
PS1 mutations 145 þ 50 129 þ 45
The mean values ( þ S.D.) are shown as pmol/min per mg pro-
tein. Signi¢cance was determined using Student’s unpaired
t-test; *P6 0.05 compared to non-mutation carriers or controls.
Fig. 1. A typical immunoblot showing the e¡ect of PdBu (1
WM) on APPs secretion in human skin ¢broblasts. The di¡erent
lanes show stimulated (+) and control (3) levels of APPs from
two individuals with (Mut) and two individuals without (wt)
the APP KM670/671NL mutation.
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tion. Western blotting of conditioned media from
cultured skin ¢broblasts using the monoclonal anti-
body 22C11 revealed the presence of a strong band
of V116 kDa. The intensity of this band increased
after PdBu treatment, consistent with a PKC-medi-
ated increase in K-secretase derived APPs.
Fig. 2 shows the optical density values for basal
and PdBu stimulated APPs secretion from ¢broblast
cell lines established from family members with and
without the Swedish APP KM670/671NL double
mutation. The mean values ( þ S.D.) of basal APPs
were 1.84 þ 0.7 in mutation-bearing cell lines and
1.32 þ 0.5 in control cells lines. Mean values
( þ S.D.) for secreted APPs following PKC stimula-
tion with 1 WM PdBu were 6.36 þ 5.2 and 7.00 þ 3.1,
respectively. The mean values ( þ S.D.) for the rela-
tive increases of APPs release after PdBu stimulation
(following subtraction of basal levels) were 4.52 þ 4.5
in mutation-bearing cell lines and 5.68 þ 3.1 in the
controls. No signi¢cant group di¡erences were seen.
The mean values ( þ S.D.) of PKC-stimulated
APPs release appeared to be lower in ¢broblasts car-
rying PS1 mutations (3.63 þ 0.9), compared to con-
trol cell lines (5.81 þ 2.7) when data from both PS1
M146V and PS1 H163Y mutation families were pooled (Fig. 3). This result did not reach accepted
levels of statistical signi¢cance. However, the relative
increase of APPs after PdBu stimulation and follow-
ing subtraction of basal release was shown to be
signi¢cantly less in mutation-bearing cell lines
(2.53 þ 0.8), compared to controls (4.12 þ 1.8,
P6 0.05, Mann^Whitney U-test). The mean values
( þ S.D.) for basal APPs release were 1.10 þ 0.5 in
cell lines carrying PS1 mutations, compared to
1.69 þ 1.0 in cells lines from controls.
Data for PKC activities and levels, as well as APPs
secretion were also analysed with respect to whether
cell lines from APP and PS1 mutation carriers had
been derived from pre-symptomatic or symptomatic
individuals. No obvious di¡erences were seen be-
tween pre-symptomatic and symptomatic individuals
for any of the parameters assayed.
4. Discussion
One of the most robust ¢ndings of abnormal sig-
nalling in Alzheimer’s disease is that of decreased
PKC activity. This de¢cit has been shown by a num-
Fig. 3. Optical density (O.D) values for basal and PdBu (1 WM)-
stimulated APPs secretion from ¢broblasts carrying the PS1
M146V and PS1 H163Y mutations (n = 7) and non-mutation
carrying cell lines (n = 7). Data are mean þ S.D. (bars) values.
Signi¢cance was determined using the Mann^Whitney U-test;
*P6 0.05 compared to non-mutation carriers when data from
both PS1 M146V and PS1 H163Y mutation families were
pooled.
Fig. 2. Optical density (O.D) values for basal and PdBu (1
WM)-stimulated APPs secretion from ¢broblasts carrying the
APP KM670/671NL mutation (n = 6; the cell line marked with
an asterisk in Table 1 was not included in this study) and non-
mutation carrying cell lines (n = 7). Data are mean þ S.D. (bars)
values. No signi¢cant group di¡erences were seen.
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ber of techniques in post-mortem Alzheimer’s disease
brain [42], as well as in peripheral skin ¢broblasts
[33^35]. In the present study, we con¢rm the results
from previous studies showing a 50% decrease of the
PKC activity in ¢broblasts established from patients
with sporadic Alzheimer’s disease, when compared to
those from healthy controls [33,34]. This decreased
PKC activity did not appear to be due to a loss of
the protein per se, since the PdBu binding assays
failed to show a decreased amount of PKC in spora-
dic Alzheimer’s disease cytosolic and particulate frac-
tions. In contrast, others have shown decreased
amounts of PKC, as determined by PdBu binding,
in sporadic Alzheimer’s disease cell lines [34,35]. Go-
voni et al. reported no signi¢cant di¡erences of the
maximal binding capacities for PdBu binding be-
tween Alzheimer’s disease and control groups in ei-
ther soluble or particulate fractions [33]. However,
these authors did show a signi¢cantly lower a⁄nity
for PdBu binding to PKC in the soluble fraction of
sporadic AD ¢broblasts (Kd = 6.3) when compared to
controls (Kd = 3.3). Bruel et al. found that the Bmax
for PdBu binding to total PKC was reduced in
sporadic Alzheimer’s disease ¢broblasts, using a sat-
urating PdBu concentration of 75 nM [34]. In the
present study we could ¢nd no di¡erence in PdBu
binding using a ligand concentration (10 nM) close
to Kd. The use of di¡erent experimental methods
might explain the discrepancies seen between the re-
ports of Bruel et al., Govoni et al., Van Huynh et al.
[35] and the data of the present study. Another ex-
planation could be that even though skin ¢broblasts
are considered as a fairly robust cell type, there is a
possibility that di¡erences between laboratories in
culturing conditions could in£uence the ¢nal result.
One should also consider the importance of appro-
priate controls in these kind of studies. This is exem-
pli¢ed by the data presented in Table 2 which shows
that soluble fraction PKC activities show consider-
able variation in control cell lines derived from dif-
ferent sources. For this reason, the familial skin ¢-
broblasts we have used may provide more
meaningful data, since the control and mutation-
bearing cell lines were derived from within the
same family.
In addition to con¢rming data from previous stud-
ies on sporadic Alzheimer’s disease cell lines, we
wanted to examine if both altered PKC activity
and PKC mediated secretory processing of APP oc-
curs in ¢broblast cell lines bearing familial Alzheim-
er’s disease causing mutations. Previous studies of
PKC activity in familial Alzheimer’s disease ¢bro-
blasts have used cell lines established from individu-
als with a history of Alzheimer’s disease but in whom
the chromosomal linkage and speci¢c gene defect
were unknown. In the present study we used cell lines
with well de¢ned APP and PS1 mutations. In addi-
tion, all familial cell lines used in this study were
established by a single investigator (Dr. Nikolaos
Venizelos) under similar conditions.
No di¡erences in either PKC activity or levels were
seen in ¢broblasts carrying the Swedish APP
KM670/671NL double mutation. We and others
have shown that other aspects of cellular signalling
in these ¢broblasts, including L-adrenoceptor-stimu-
lated adenylyl cyclase activity, internal calcium regu-
lation and levels of the large GsK subunit, are less
a¡ected than in ¢broblasts established from sporadic
Alzheimer’s disease cases or ¢broblasts carrying PS1
mutations [43^45]. Fibroblasts with the Swedish APP
KM670/671NL mutation did not show an apparent
change in PKC-mediated K-secretase APP processing
which is in agreement with the ¢ndings of Citron et
al [20]. Since there are no reports of an altered sig-
nalling in the family carrying the APP KM670/
671NL mutation, it is likely that the increased
amounts of AL seen in this family are due solely to
the e¡ects of the mutation on APP processing. The
APP KM670/671NL mutation is situated at a site
just N-terminal of the L-amyloid peptide were APP
is cleaved by L-secretase. Haass and colleagues have
hypothesised that the increased production and se-
cretion of AL originated from Swedish APP
KM670/671NL mutation is due to a competition be-
tween the K- and L-secretases that occurs in the Gol-
gi-derived vesicles [46].
Pooling of data from both the PS1 M146V and
PS1 H163Y mutation families revealed a signi¢cant
30% increase of PKC levels in mutation-bearing,
compared to control cell lines. These changes in
PKC levels did not appear to be accompanied by
altered PKC activities. This observation of increased
PKC levels without a change in enzyme activity
would suggest an increased production of inactive
PKC protein in PS1 mutation-bearing ¢broblasts.
The mechanism by which PS1 mutations shift APP
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processing into the more amyloidogenic way result-
ing in increased AL 1^42 levels remains to be re-
solved. It was shown recently that PS1 is involved
in the Q-secretase-mediated proteolytic cleavage of
APP, and it has been hypothesised that PS1 might
function in some way as a regulatory cofactor of the
Q-secretase [47].
The relative increase of APPs secretion after PdBu
stimulation was shown to be signi¢cantly lower in
PS1 mutation-bearing cell lines, compared to con-
trols, when data was controlled for basal release.
This indicates that PS1 mutations result in a de-
creased PKC-mediated K-secretase APP processing,
independently of gross alterations in PKC levels
and activity. Ancolio et al. recently showed that
HEK293 cells transfected with mutated PS1 secreted
lower amounts of K-secretase derived APPs [48]. The
results of the present study provide an important
con¢rmation that decreased K-secretase derived
APP due to PS1 mutations does not represent an
artefact due to PS overexpression. Together, these
results imply that PS1 mutations limit the amount
of APP available for PKC-mediated K-secretase
APP processing and therefore shift the APP process-
ing into an amyloidogenic pathway leading to in-
creased amount of AL.
In summary, previous studies of PKC-regulated
APP processing in Alzheimer’s disease have been car-
ried out in cell lines established from sporadic Alz-
heimer’s disease cases or in transfected cell lines of
di¡erent origin. In the present study we demonstrate
that the levels and activity of PKC as well as the
PKC-mediated K-secretase processing of APP are
di¡erentially a¡ected in skin ¢broblasts established
from sporadic Alzheimer’s disease cases when com-
pared to cell lines established from individuals with
familial Alzheimer’s disease APP KM670/671NL,
PS1 M146V and PS1 H163Y mutations. When taken
together with results from other studies, our data
suggest that in sporadic cases a decreased PKC ac-
tivity is likely to limit non-amyloidogenic APP proc-
essing leading to increased AL production. In the
APP KM670/671NL mutation bearing cell lines it
is the mutation itself, rather than a de¢cit in PKC,
that gives rise to increased levels of AL seen in af-
fected family members. Similarly, the reported in-
crease in AL production from PS1 mutation-bearing
lines [25^28] occurs due to an e¡ect of the mutation
on APP processing [47] rather than due to a gross
PKC de¢cit. Therefore, many di¡erent mechanisms
could lead to a common pathology of increased AL
in sporadic and familial forms of Alzheimer’s dis-
ease.
Acknowledgements
We thank Dr. Nikolaus Venizelos for establishing
the cell lines from all the familial individuals. This
study was supported by research grants from The
Swedish Medical Research Council (K97-19X-
12244-01A), the European Union Biomed-2 con-
certed action (contract number bmh4-ct-96-0162),
Axel och Margareta Ax:son Johnsons Foundation,
Stiftelsen fo«r Gamla Tja«narinnor, Loo and Hans Os-
terman’s Foundation, Karolinska Institute research
fund, Stiftelsen Sigurd and Elsa Goljes Minne, Eva
and Oscar Ahre¤n Research Foundation, Stockholm.
References
[1] G. Glenner, C.W. Wong, Alzheimer’s disease: initial report
of the puri¢cation and characterization of a novel cerebro-
vascular amyloid protein, Biochem. Biophys. Res. Commun.
120 (1984) 885^890.
[2] S. Khatoon, I. Grundke-Iqbal, K. Iqbal, Brain levels of mi-
crotubule-associated protein d are elevated in Alzheimer’s
disease: a radio-immuno-slot-blot assay for nanograms of
the protein, J. Neurochem. 59 (1992) 750^753.
[3] F.S. Esch, P.S. Keim, E.C. Beattie, R.W. Blacher, A.R. Cul-
well, T. Oltersdorf, D. McClure, P. Ward, Cleavage of amy-
loid L peptide during constitutive processing of its precursor,
Science 248 (1990) 1122^1124.
[4] S.S. Sisodia, E.H. Koo, K. Beyreuther, A. Unterbeck, D.L.
Price, Evidence that L-amyloid protein in Alzheimer’s dis-
ease is not derived by normal processing, Science 248
(1990) 492^495.
[5] T.E. Golde, S. Estus, L.H. Younkin, D.J. Selkoe, S.G.
Younkin, Processing of the amyloid protein precursor to
potentially amyloidogenic derivatives, Science 255 (1992)
728^730.
[6] C. Haass, A.Y. Hung, M.G. Schlossmacher, D.B. Teplow,
D.J. Selkoe, L-Amyloid peptide and a 3-kDa fragment are
derived by distinct cellular mechanisms, J. Biol. Chem. 268
(1993) 3021^3024.
[7] J. Na«slund, M. Jensen, L.O. Tjernberg, J. Thyberg, L. Ter-
enius, C. Nordstedt, The metabolic pathway generating p3,
an AL-peptide fragment, is probably non-amyloidogenic,
Biophys. Res. Commun. 204 (1994) 780^787.
BBADIS 61813 22-3-99
M. Vestling et al. / Biochimica et Biophysica Acta 1453 (1999) 341^350348
[8] S. Estus, T.E. Golde, T. Kinishita, D. Blades, D. Lowery,
M. Eisen, M. Usiak, X. Qu, T. Tabira, B.D. Greenberg, S.G.
Younkin, Potentially amyloidogenic, carboxyterminal deriv-
atives of the amyloid protein precursor, Science 255 (1992)
726^728.
[9] J.D. Buxbaum, M. Oishi, H.I. Chen, R. Pinkas-Kramarski,
E.A. Ja¡e, S.E. Gandy, P. Greengard, Cholinergic agonists
and interleukin 1 regulate processing and secretion of the
Alzheimer L/A4 amyloid protein precursor, Proc. Natl.
Acad. Sci. U.S.A. 89 (1992) 10075^10078.
[10] G.L. Caporaso, S.E. Gandy, J.D. Buxbaum, T.V. Ramabha-
dran, P. Greengard, Protein phosphorylation regulates secre-
tion of Alzheimer L/A4 amyloid precursor protein, Proc.
Natl. Acad. Sci. U.S.A. 89 (1992) 3055^3059.
[11] S.L. Gillespie, T.E. Golde, S.G. Younkin, Secretory process-
ing of the Alzheimer amyloid L/A4 protein precursor is in-
creased by protein phosphorylation, Biochem. Biophys. Res.
Commun. 187 (1992) 1285^1290.
[12] R.M. Nitsch, B.E. Slack, R.J. Wurtman, J.H. Growdon,
Release of Alzheimer amyloid precursor derivates stimulated
by activation of muscarinic acetylcholine receptors, Science
258 (1992) 304^307.
[13] B.E. Slack, J. Breu, M.A. Petryniak, K. Srivastava, R. Wurt-
man, Tyrosine phosphorylation-dependent stimulation of
amyloid precursor protein secretion by the m3 muscarinic
acetylcholine receptor, J. Biol. Chem. 270 (1995) 8337^8344.
[14] H. Xu, P. Greengard, S. Gandy, Regulated formation of
golgi secretory vesicles containing Alzheimer L-amyloid pre-
cursor protein, J. Biol. Chem. 270 (1995) 23243^23245.
[15] A.C. LeBlanc, M. Koutroumanis, C.G. Goodyer, Protein
kinase C activation release of secreted amyloid precursor
protein without decreasing AL production in human primary
neuron cultures, J. Neurosci. 18 (1998) 2907^2913.
[16] J.D. Buxbaum, A.A. Rue£i, C.A. Parker, A.M. Cypess, P.
Greengard, Calcium regulates processing of the Alzheimer
amyloid protein precursor in a protein kinase C-independent
manner, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4489^4493.
[17] D. Gabuzda, J. Busciglio, B.A. Yanker, Inhibition of L-amy-
loid production by activation of protein kinase C, J. Neuro-
chem. 61 (1993) 2326^2329.
[18] A.Y. Hung, C. Haass, R.M. Nitsch, W.Q. Qiu, M. Citron,
R.J. Wurtman, J.H. Growdon, D.J. Selkoe, Activation of
protein kinase C inhibits cellular production of the amyloid
L-protein, J. Biol. Chem. 268 (1993) 22959^22962.
[19] J.S. Jacobsen, M.A. Spruyt, A.M. Brown, S.R. Sahasra-
budhe, A.J. Blume, M.P. Vitek, H.A. Muenkel, J. Sonnen-
berg-Reines, The release of Alzheimer’s disease L amyloid
peptide is reduced by phorbol treatment, J. Biol. Chem.
269 (1994) 8376^8382.
[20] M. Citron, C. Vigo-Pelfrey, D.B. Teplow, C. Miller, D.
Schenk, J. Johnston, B. Winblad, N. Venizelos, L. Lannfelt,
D.J. Selkoe, Excessive production of amyloid L-protein by
peripheral cells of symptomatic and presymptomatic patients
carrying the Swedish familial Alzheimer disease mutation,
Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11993^11997.
[21] T. Dyrks, U. Mo«nning, K. Beyreuther, J. Turner, Amyloid
precursor protein secretion and LA4 amyloid generation are
not mutually exclusive, FEBS Lett. 349 (1994) 210^214.
[22] M. Mullan, F. Crawford, K. Axelman, H. Houlden, L. Lil-
ius, B. Winblad, L. Lannfelt, A pathogenic mutation for
probable Alzheimer’s disease in the APP gene at the N-ter-
minus of L-amyloid, Nat. Genet. 1 (1992) 345^347.
[23] J.A. Johnston, R.F. Cowburn, S. Norgren, B. Wiehager, N.
Venizelos, B. Winblad, C. Vigo-Pelfrey, D. Schenk, L. Lann-
felt, C. O’Neill, Increased L-amyloid release and levels of
amyloid precursor protein (APP) in ¢broblast cell lines
from family members with the Swedish Alzheimer’s disease
APP670/671 mutation, FEBS Lett. 354 (1994) 274^278.
[24] R.F. Clark, M. Hutton, R.A. Fuldner, S. Froelich, E. Kar-
ran, C. Talbot et al., The structure of the Presenilin 1 (S182)
gene and identi¢cation of six novel mutations in early onset
AD families, Nat. Genet. 11 (1995) 219^222.
[25] K. Du¡, C. Eckman, C. Zehr, X. Yu, C.-M. Prada, J. Perez-
tur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, D. Mor-
gan, M.N. Gordon, L. Holcomb, L. Refolo, B. Zenk, J.
Hardy, S. Younkin, Increased amyloid-L42(43) in brains of
mice expressing mutant presenilin 1, Nature 383 (1996) 710^
713.
[26] D.R. Borchelt, G. Thinakaran, C.B. Eckman, M.K. Lee, F.
Davenport, T. Ratovisky, C.M. Prada, G. Kim, S. Seekins,
D. Yager, H.H. Slunt, R. Wang, M. Seeger, A.I. Levey, S.E.
Gandy, N.G. Copeland, N.A. Jenkins, D.L. Price, S.G.
Younkin, S.S. Sisodia, Familial Alzheimer’s disease-linked
presenilin 1 variants elevate AL1-42/1-40 ratio in vitro and
in vivo, Neuron 17 (1996) 1005^1013.
[27] M. Citron, D. Westaway, W. Xia, G. Carlson, T. Diehl, G.
Levesque, K. Johnson-Wood, M. Lee, P. Seubert, A. Davis,
D. Kholodenko, R. Motter, R. Sherrington, B. Perry, H.
Yao, R. Strome, I. Lieberburg, J. Rommens, S. Kim, D.
Schenk, P. Fraser, P. St George-Hyslop, D.J. Selkoe, Mu-
tant presenilins of Alzheimer’s disease increase production of
42-residue amyloid L-protein in both transfected cells and
transgenic mice, Nat. Med. 3 (1997) 67^72.
[28] W. Xia, J. Zhang, D. Kholodenko, M. Citron, M.B. Pod-
lisny, D.B. Teplow, C. Haass, P. Seubert, E.H. Koo, D.J.
Selkoe, Enhanced production and oligomerization of the 42-
residue amyloid L-protein by Chinese hamster ovary cells
stably expressing mutant presenilins, J. Biol. Chem. 272
(1997) 7977^7982.
[29] D. Scheuner, C. Eckman, M. Jensen, X. Song, M. Citron, N.
Suzuki, T.D. Bird, J. Hardy, M. Hutton, W. Kukull, E.
Larson, E. Levy-Lahad, M. Viitanen, E. Peskind, P. Poor-
kaj, G. Schellenberg, R. Tanzi, W. Wasco, L. Lannfelt, D.
Selkoe, S. Younkin, Secreted amyloid L-protein similar to
that in the senile plaques of Alzheimer’s disease is increased
in vivo by the presenilin 1 and 2 and APP mutations linked
to familial Alzheimer’s disease, Nat. Med. 2 (1996) 864^
870.
[30] R.N. Martins, B.A. Turner, R.T. Carroll, D. Sweeney, K.S.
Kim, H.M. Wisniewski, J.P. Blass, G.E. Gibson, S. Gandy,
High levels of amyloid-L protein from S182 (Glu246) familial
Alzheimer’s cells, Neuroreport 7 (1995) 217^220.
BBADIS 61813 22-3-99
M. Vestling et al. / Biochimica et Biophysica Acta 1453 (1999) 341^350 349
[31] H.-M. Huang, R. Martins, S. Gandy, R. Etcheberrigaray, E.
Ito, D.L. Alkon, J. Blass, G. Gibson, Use of cultured ¢bro-
blasts in elucidating the pathophysiology and diagnosis of
Alzheimer’s disease, Ann. N.Y. Acad. Sci. 747 (1994) 225^
244.
[32] S. Govoni, L. Gasparini, M. Racchi, M. Trabucchi, Periph-
eral cells as an investigational tool for Alzheimer’s disease,
Life Sci. 59 (1996) 461^468.
[33] S. Govoni, S. Bergamaschi, M. Racchi, F. Battaini, G. Bi-
netti, A. Bianchetti, M. Trabucchi, Cytosol protein kinase C
downregulation in ¢broblasts from Alzheimer’s disease pa-
tients, Neurology 43 (1993) 2581^2586.
[34] A. Bruel, G. Cherqui, S. Columelli, D. Margelin, M. Roud-
ier, P. Sinet, M. Prieur, J. Pe¤rignon, J. Delabar, Reduced
protein kinase C activity in sporadic Alzheimer’s disease ¢-
broblasts, Neurosci. Lett. 133 (1991) 89^92.
[35] T. Van Huynh, G. Cole, R. Katzman, K. Huang, T. Saitoh,
Reduced protein kinase C immunoreactivity and altered pro-
tein phosphorylation in Alzheimer’s disease ¢broblasts,
Arch. Neurol. 46 (1989) 1195^1199.
[36] M. Racchi, S. Bergamaschi, S. Govoni, W.C. Wetsel, A.
Bianchetti, G. Binetti, F. Battaini, M. Trabucchi, Character-
ization and distribution of protein kinase C isoforms in hu-
man skin ¢broblasts, Arch. Biochem. Biophys. 314 (1994)
107^111.
[37] S. Bergamaschi, G. Binetti, S. Govoni, W.C. Wetsel, F. Bat-
taini, M. Trabucchi, A. Bianchetti, M. Racchi, Defective
phorbol ester-stimulated secretion of L-amyloid precursor
protein from Alzheimer’s disease ¢broblasts, Neurosci.
Lett. 201 (1995) 1^4.
[38] M.M. Bradford, A rapid and sensitive method for the quan-
ti¢cation of microgram quantities of protein utilizing the
principle of protein-dye binding, Anal. Biochem. 72 (1976)
249^254.
[39] K.-P. Huang, The mechanism of protein kinase C activation,
Trends Neurosci. 12 (1989) 425^432.
[40] L.V. Dekker, P.J. Parker, Protein kinase C ^ a question of
speci¢city, Trends Biochem. Sci. 19 (1994) 73^77.
[41] U.K. Laemmli, Cleavage of structural proteins during the
assembly of the head of bacteriophage T4, Nature 227
(1970) 680^685.
[42] C.J. Fowler, The role of the phosphoinositide signalling sys-
tem in the pathogenesis of sporadic Alzheimer’s disease: a
hypothesis, Brain Res. Rev. 25 (1997) 373^380.
[43] M. Vestling, A. Adem, M. Racchi, G.E. Gibson, L. Lann-
felt, R.F. Cowburn, Di¡erential regulation of adenylyl cy-
clase in ¢broblasts from sporadic and familial Alzheimer’s
disease cases with PS1 and APP mutations, Neuroreport 8
(1997) 2031^2035.
[44] G.E. Gibson, M. Vestling, H. Zhang, S. Szolosi, D. Alkon,
L. Lannfelt, S. Gandy, R.F. Cowburn, Abnormalities in
Alzheimer’s disease ¢broblasts bearing the APP670/671 mu-
tation, Neurobiol. Aging 18 (1997) 573^580.
[45] C. Shanahan, G.E. Gibson, R.F. Cowburn, J.A. Johnston,
B. Wiehager, L. Lannfelt, C. O’Neill, G protein subunit
levels in ¢broblasts from familial Alzheimer’s disease pa-
tients: lower levels of the high molecular weight GsK isoform
in patients with decreased L-adrenergic receptor stimulated
cAMP formation, Neurosci. Lett. 232 (1997) 33^36.
[46] C. Haass, C.A. Lemere, A. Capell, M. Citron, P. Seubert, D.
Schenk, L. Lannfelt, D.J. Selkoe, The Swedish mutation
causes early-onset Alzheimer’s disease by L-secretase cleav-
age within the secretory pathway, Nat. Med. 1 (1995) 1291^
1296.
[47] B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele,
G. Guhde, W. Annaert, K. Von Figura, F. Van Leuven,
De¢ciency of presenilin-1 inhibits the normal cleavage of
amyloid precursor protein, Nature 391 (1998) 387^390.
[48] K. Ancolio, P. Marambaud, P. Dauch, F. Checler, K-Secre-
tase-derived product of L-amyloid precursor protein is de-
creased by presenilin 1 mutations linked to familial Alzheim-
er’s disease, J. Neurochem. 69 (1997) 2494^2499.
BBADIS 61813 22-3-99
M. Vestling et al. / Biochimica et Biophysica Acta 1453 (1999) 341^350350
